Market Research Logo

Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)

Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)

Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Side vision may begin to decrease followed by central vision resulting in blindness, if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent.

Though, glaucoma cannot be cured completely but the disease progression can be controlled with the help of available treatments. There are three types of modalities available for treatment of glaucoma: Drugs, Laser and Invasive Surgery. Further, based upon the approaches employed for the medication, it can be segmented into two parts: PGA Medication and Non-PGA Medication. The PGA approach reduces IOP with the help of prostaglandin (PGA). The non-PGA medication can be further divided into four sub segments: Beta blockers, Alpha blockers, Carbonic anhydrase inhibitors (CAIs) and Combination Products.

Several factors such as rising prevalence of diabetes, growing geriatric population and rising health care expenditure along with increasing disposable income and growing obese population will drive the market growth in the next few years. Development of new drugs & devices and drug therapy focused upon IOP are the few notable market trends. However, high cost of treatment, severe side effects and hasty drug approval processes act as a major roadblock for the market growth.

The report “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on the US and OUS treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Novartis AG, Merck & Co., Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global glaucoma market along with the study of the US market."


1. Overview
1.1 Glaucoma
1.2 Causes & Types
Table 1: Types of Glaucoma
1.3 Symptoms & Diagnosis
Table 2: Causes of Epilepsy
1.4 Treatment Methods
Table 3: Treatments Available for Glaucoma
1.5 Glaucoma Pharmaceutical Market Segmentation
Table 4: Glaucoma Pharmaceutical Market by Segment
2. Global Glaucoma Market
2.1 Global Glaucoma Market Forecast by Value
Table 5: Global Glaucoma Market Forecast by Value (2016-2021)
2.2 Global Glaucoma Market by Segments
Table 6: Global Glaucoma Market by Segments (2016)
2.3 Global Glaucoma Drugs Market Forecast by Value
Table 7: Global Glaucoma Drugs Market Forecast by Value (2016-2021)
2.4 Global Glaucoma Market by Drug Class
Table 8: Global Glaucoma Market by Drug Class (2016)
2.5 Global Glaucoma Drugs Market by Region
Table 9: Global Glaucoma Drugs Market by Region (2016)
2.6 Global Glaucoma Patient Volume Forecast
Table 10: Global Glaucoma Patient Volume Forecast (2016-2021)
3. Regional Markets
3.1 The US
3.1.1 The US Glaucoma Drugs Market Forecast by Value
Table 11: The US Glaucoma Drugs Market Forecast by Value (2016-2021)
3.1.2 The US Glaucoma Patient Volume Forecast
Table 12: The US Glaucoma Patient Volume Forecast (2016-2021)
3.1.3 The US Open Angle Glaucoma Patient Volume Forecast
Table 13: The US Open Angle Glaucoma Patient Volume Forecast (2016-2021)
3.1.4 The US Glaucoma Prescription Volume Forecast
Table 14: The US Glaucoma Prescription Volume Forecast (2016-2021)
3.1.5 The US Glaucoma Drugs Market by Type
Table 15: The US Glaucoma Drug Market by Type (2016)
3.1.6 The US Glaucoma First Line Drugs Market Forecast by Value
Table 16: The US Glaucoma First Line Drugs Market Forecast by Value (2016-2021)
3.1.7 The US Glaucoma First Line Drugs Prescription Volume Forecast
Table 17: The US Glaucoma First Line Drugs Prescription Volume Forecast (2016-2021)
3.1.8 The US Glaucoma Second Line Drugs Market Forecast by Value
Table 18: The US Glaucoma Second Line Drugs Market Forecast by Value (2016-2021)
3.1.9 The US Glaucoma Second Line Drugs Prescription Volume Forecast
Table 19: The US Glaucoma Second Line Drugs Prescription Volume Forecast (2016-2021)
3.1.10 The US MIGS Procedure Volume Forecast
Table 20: The US MIGS Procedure Volume Forecast (2016-2021)
3.2 The OUS
3.2.1 OUS Glaucoma Drugs Market Forecast by Value
Table 21: OUS Glaucoma Drugs Market Forecast by Value (2016-2021)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Prevalence of Diabetes
Table 22: Global Type 2 Diabetes Patients Population Forecast (2016-2021)
4.1.2 Growing Geriatric Population
Table 23: Global Population Older than 60 years (2012-2016)
4.1.3 Rising Healthcare Expenditure
Table 24: Global Per Capita Healthcare Expenditure (2012-2016)
4.1.4 Rising Disposable Income
Table 25: Global GDP per Capita (2012-2016)
4.1.5 Growing Obese Population
Table 26: Global Obese Population (2012-2016)
4.2 Key Trends & Development
4.2.1 Development of New Drugs and Therapies
Table 27: New Glaucoma Drugs and Therapy Devices in Pipeline (2016)
4.2.2 Drug Therapies Target Intraocular Pressure
4.3 Challenges
4.3.1 High Cost
4.3.2 Side Effects
4.3.3 Hasty Drug Approval Process
Table 28: Drug Approval Process
5. Competitive Landscape
5.1 Global Glaucoma Market
5.1.1 Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison
Table 29: Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison (2016)
5.2 The US
5.2.1 The US Glaucoma First Line Drugs Market Share by Company
Table 30: The US Glaucoma First Line Drugs Market Share by Company (2016/2021)
5.2.2 The US Glaucoma Second Line Drugs Market Share by Company
Table 31: The US Glaucoma Second Line Drugs Market Share by Company (2016/2021)
5.2.3 The US MIGS Market Share by Company
Table 32: The US MIGS Market Share by Company (2016/2021)
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
Table 33: Pfizer Inc. Revenue by Segment (2016)
6.1.2 Financial Overview
Table 34: Pfizer Inc.’s Revenue and Net Income (2012-2016)
6.1.3 Business Strategies
Table 35: Pfizer Inc. R&D Expenses (2015-2016)
Table 6.1: Major Product Developments by Pfizer Inc. (Since November 1, 2016)
6.2 Novartis AG
6.2.1 Business Overview
Table 36: Novartis AG Net Sales by Segment (2016)
6.2.2 Financial Overview
Table 37: Novartis AG Net Sales and Net Income (2012-2016)
6.2.3 Business Strategies
Table 38: Novartis AG R&D Expenditure (2014-2016)
6.3 Merck & Co., Inc.
6.3.1 Business Overview
Table 39: Merck & Co., Inc. Sales by Segment (2016)
6.3.2 Financial Overview
Table 40: Merck & Co., Inc.’s Sales and Net Income (2012-2016)
6.3.3 Business Strategies
Table 41: Merck & Co., Inc.’s R&D Expenditure (2014-2016)
6.4 Allergan Plc.
6.4.1 Business Overview
Table 42: Allergan Plc. Net Revenue by Segment (2016)
6.4.2 Financial Overview
Table 43: Allergan Plc. Net Revenue and Net Income (2012-2016)
6.4.3 Business Strategies
Table 44: Allergan Plc. R&D Expenditure (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report